Nieman Lynnette K, Biller Beverly M K, Findling James W, Murad M Hassan, Newell-Price John, Savage Martin O, Tabarin Antoine
Program in Reproductive and Adult Endocrinology (L.K.N.), The Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892; Neuroendocrine Unit (B.M.K.B.), Massachusetts General Hospital, Boston, Massachusetts 02114; Medical College of Wisconsin (J.W.F.), Milwaukee, Wisconsin 53226; Mayo Clinic (M.H.M.), Division of Preventive Medicine, Rochester, Minnesota 55905; Department of Human Metabolism (J.N.-P.), School of Medicine and Biomedical Science, University of Sheffield, Sheffield S10 2RX, United Kingdom; William Harvey Research Institute (M.O.S.), Barts and the London School of Medicine and Dentistry, London EC1M 6BQ, United Kingdom; and Department of Endocrinology (A.T.), Centre Hospitalier Universitaire de Bordeaux and Inserm 862, University of Bordeaux, 33077 Bordeaux, France.
J Clin Endocrinol Metab. 2015 Aug;100(8):2807-31. doi: 10.1210/jc.2015-1818. Epub 2015 Jul 29.
The objective is to formulate clinical practice guidelines for treating Cushing's syndrome.
Participants include an Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. The European Society for Endocrinology co-sponsored the guideline.
The Task Force used the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews and used the best available evidence from other published systematic reviews and individual studies.
The Task Force achieved consensus through one group meeting, several conference calls, and numerous e-mail communications. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines.
Treatment of Cushing's syndrome is essential to reduce mortality and associated comorbidities. Effective treatment includes the normalization of cortisol levels or action. It also includes the normalization of comorbidities via directly treating the cause of Cushing's syndrome and by adjunctive treatments (eg, antihypertensives). Surgical resection of the causal lesion(s) is generally the first-line approach. The choice of second-line treatments, including medication, bilateral adrenalectomy, and radiation therapy (for corticotrope tumors), must be individualized to each patient.
制定库欣综合征的临床实践指南。
参与者包括内分泌学会任命的专家特别工作组、一名方法学家和一名医学撰写人。欧洲内分泌学会共同赞助了该指南。
特别工作组使用推荐分级、评估、制定和评价系统来描述推荐的强度和证据的质量。特别工作组委托进行了三项系统评价,并使用了其他已发表的系统评价和个体研究中可得的最佳证据。
特别工作组通过一次小组会议、几次电话会议和大量电子邮件沟通达成共识。内分泌学会和欧洲内分泌学会的委员会及成员对这些指南的初稿进行了审查并提出了意见。
治疗库欣综合征对于降低死亡率和相关合并症至关重要。有效的治疗包括使皮质醇水平或作用恢复正常。还包括通过直接治疗库欣综合征的病因和辅助治疗(如抗高血压药)使合并症恢复正常。手术切除病因性病变通常是一线治疗方法。二线治疗的选择,包括药物治疗、双侧肾上腺切除术和放射治疗(用于促肾上腺皮质激素瘤),必须针对每个患者进行个体化选择。